H.C. Wainwright lowered the firm’s price target on Arcus Biosciences (RCUS) to $18 from $20 and keeps a Buy rating on the shares after the company hosted a conference call to discuss updated data for casdatifan from the ARC-20 study for treatment of clear cell renal cell carcinoma that were presented at ASCO-GU over the weekend. The company also announced that Gilead’s (GILD) opt-in period for casdatifan has expired without the company choosing to opt-in, to the firm’s “surprise,” though Gilead did participate in the $150M equity raise that was also announced this morning, the analyst tells investors. The firm updated its model to remove Gilead collaboration estimates for casdatifan, including the $150M milestone it was estimating, and instead has modeled in the $150M equity raise that was announced this morning.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCUS:
- Arcus Biosciences price target lowered to $25 from $36 at Morgan Stanley
- Arcus Biosciences retains rights to casdatifan
- Arcus Biosciences prices 13.6M shares at $11.00 in underwritten offering
- Arcus Biosciences’ Casdatifan: Promising Efficacy and Safety Profile Highlights Buy Rating
- Arcus Biosciences 13.6M share Secondary priced at $11.00
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue